Nemtabrutinib + Venetoclax for Chronic Lymphocytic Leukemia

This trial explores the combined effectiveness of two drugs, nemtabrutinib and venetoclax, in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Nemtabrutinib blocks a protein that promotes cancer cell growth, while venetoclax inhibits a protein that sustains cancer cell survival. The goal is to determine if using both drugs can kill more cancer cells. Individuals with CLL or SLL who have not received prior treatment and experience symptoms like significant fatigue or unexplained weight loss might be suitable candidates for this trial. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial requires a washout period (time without taking certain medications) for drugs that are P-glycoprotein substrates, CYP3A strong inducers, or CYP3A strong inhibitors. You should discuss your current medications with the trial team to see if they fall into these categories.

Research has shown that combining nemtabrutinib and venetoclax is promising for safety in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Studies have found that this combination has a manageable safety profile, indicating that while side effects exist, they are not severe and doctors can manage them.

One study found that taking 45 mg of nemtabrutinib with venetoclax led to a 100% response rate in patients whose cancer had returned or was resistant to previous treatments. The side effects were considered manageable, meaning they were not too severe or difficult to handle.

Researchers are excited about the combination of nemtabrutinib and venetoclax for treating chronic lymphocytic leukemia (CLL) because it offers a novel approach compared to current treatments. Unlike standard therapies, which often target single pathways, nemtabrutinib and venetoclax work together to disrupt multiple cancer cell survival mechanisms. Nemtabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor, which blocks signals that help cancer cells grow, while venetoclax helps induce cancer cell death by inhibiting the BCL-2 protein. This dual-action strategy has the potential to be more effective in managing CLL than traditional treatments.

Research has shown that combining nemtabrutinib and venetoclax may effectively treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In studies involving patients whose CLL/SLL returned or did not respond to other treatments, this combination achieved a 100% overall response rate (ORR), with every patient experiencing some tumor shrinkage. In this trial, participants will receive both nemtabrutinib and venetoclax. Venetoclax blocks a protein essential for cancer cell survival, while nemtabrutinib targets another protein to halt cancer growth. Early results suggest that these drugs together might outperform some current treatments. The combination has also demonstrated manageable safety, offering hope for patients.¹²³⁴⁶